OriGen Biomedical voluntarily recalled a lot of its 51 VV13F Reinforced Dual Lumen ECMO Catheters, according to the company and the FDA.

The NIH has launched a randomized, multicenter, international study to see if statins can reduce the risk of cardiovascular disease in HIV patients. As of now, no therapies have been found to lower cardiovascular risk in this patient population.

There is a big gap between studies using animal models and humans, but preliminary research is showing that exercise during pregnancy may ward off fetal heart defects, according to the New York Times.

The FDA approved ivabradine to reduce the risk of hospitalization in patients with heart failure. The agency had expedited its evaluation of the drug under its priority review program.

An FDA advisory panel recommended the approval of cangrelor to reduce the risk of periprocedural thrombotic events in patients with coronary artery disease undergoing PCI.

An FDA advisory panel recommended that labeling for the diabetes drug saxagliptin include a warning about a risk of heart failure. The panel determined that the drug’s overall cardiovascular risk was acceptable.

Medtronic plc (NYSE: MDT) today announced it has received CE (Conformité Européenne) Mark of the Micra® Transcatheter Pacing System (TPS), the world’s smallest pacemaker. At less than one-tenth the size of traditional pacemakers, the Micra device provides the most advanced pacing technology available while being cosmetically invisible and small enough to be delivered with minimally invasive techniques through a catheter, and implanted directly into the heart.

The Society for Cardiovascular Angiography and Interventions’ (SCAI) 2015 scientific session will flash some big names on its marque this year, with PROMETHEUS, ORBIT II and other trials scheduled to make an appearance.